Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

vTv Therapeutics (VTVT) EBITDA Margin (2016 - 2024)

vTv Therapeutics' EBITDA Margin history spans 10 years, with the latest figure at 28776.47% for Q4 2024.

  • For Q4 2024, EBITDA Margin changed N/A year-over-year to 28776.47%; the TTM value through Sep 2025 reached 175382.35%, down 17298285.0%, while the annual FY2024 figure was 2377.58%, N/A changed from the prior year.
  • EBITDA Margin for Q4 2024 was 28776.47% at vTv Therapeutics, down from 562.7% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 28.6% in Q4 2020 and bottomed at 123433.33% in Q4 2021.
  • The 4-year median for EBITDA Margin is 34616.81% (2024), against an average of 37016.52%.
  • The largest annual shift saw EBITDA Margin soared 9128574bps in 2020 before it crashed -12346193bps in 2021.
  • A 4-year view of EBITDA Margin shows it stood at 28.6% in 2020, then plummeted by -431712bps to 123433.33% in 2021, then surged by 43bps to 70477.78% in 2022, then skyrocketed by 59bps to 28776.47% in 2024.
  • Per Business Quant, the three most recent readings for VTVT's EBITDA Margin are 28776.47% (Q4 2024), 562.7% (Q1 2024), and 70477.78% (Q4 2022).